Tertiary lymphoid structures (TLS) are increasingly recognized to have roles in cancer. Within tumor microenvironments (TME), TLS can arise as ectopic lymphoid organs containing aggregates of ...

Immune checkpoint inhibitor therapy for any cancer was associated with a significant reduction of actinic keratoses, ...

A 40-gene expression profile (40-GEP) test can improve risk stratification of patients with cutaneous squamous cell carcinoma (CSCC), according to research presented at the NCCN Annual Conference 2025 ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 15.53%, which has investors questioning if this is right time to buy.

D. Boral Capital reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a research ...

As of December 31, 2024, Fortress’ consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as of September 30, 2024, and $80.9 million as of December 31, 2023, a ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Reports FY24 revenue $41k vs $103k last yearLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...